Bortezomib

Jun 03, 2018
Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of Andromeda
Background: Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells…
Read more
Oct 05, 2017
Pitfalls in Conducting Prospective Trials in Stage III Cardiac Amyloidosis - Experience from the REVEAL Study
Very few prospective clinical trials have been conducted in advanced cardiac AL amyloidosis due to the rarity of the disease and challenging clinical course of the…
Read more
Sep 26, 2017
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Survival for Patients With AL Amyloidosis Receiving Bortezomib-Based Treatment
AL amyloidosis is a rare plasma cell dyscrasia characterized by multi-organ involvement and poor prognosis. We retrospectively evaluated the organ response (OR) and…
Read more
Subscribe to